BACKGROUND: Barrett's esophagus (BE) is known to progress to esophageal adenocarcinoma in a setting of chronic inflammation. Toll-like receptor (TLR) 4 has been linked to inflammation-associated carcinogenesis. We aimed to determine the expression and functional activity of TLR4 in the esophagus and whether TLR4 activation in BE could promote carcinogenesis by inducing COX-2 expression. METHODS: TLR4 expression in esophageal adenocarcinoma, BE, duodenum, reflux esophagitis and normal squamous esophagus biopsies was assessed using real-time PCR and validated by in situ hybridization and immunohistochemistry. Ex vivo cultures of BE, duodenum and normal squamous esophagus biopsies and a BE cell line (BAR-T) were stimulated with the TLR4 agonist lipopolysaccharide (LPS). To evaluate the effect of TLR4 activation, NF-κB activation, IL8 secretion and expression and COX-2 expression were determined. RESULTS: TLR4 expression was significantly increased in esophageal adenocarcinoma, BE, duodenum and reflux esophagitis compared to normal squamous esophagus. LPS stimulation resulted in NF-κB activation and a dose-dependent increase of IL8 secretion and mRNA expression. The induction of IL8 was more evident in BE compared to normal squamous esophagus. Upon LPS stimulation, COX-2 expression increased significantly in ex vivo cultured BE biopsies, which was observed in both epithelium and lamina propria cells. However, no effect was found in duodenum and normal squamous esophagus biopsies. CONCLUSION: TLR4 activation in BE results in a strong increase in COX-2 and may contribute to malignant transformation.
BACKGROUND:Barrett's esophagus (BE) is known to progress to esophageal adenocarcinoma in a setting of chronic inflammation. Toll-like receptor (TLR) 4 has been linked to inflammation-associated carcinogenesis. We aimed to determine the expression and functional activity of TLR4 in the esophagus and whether TLR4 activation in BE could promote carcinogenesis by inducing COX-2 expression. METHODS:TLR4 expression in esophageal adenocarcinoma, BE, duodenum, reflux esophagitis and normal squamous esophagus biopsies was assessed using real-time PCR and validated by in situ hybridization and immunohistochemistry. Ex vivo cultures of BE, duodenum and normal squamous esophagus biopsies and a BE cell line (BAR-T) were stimulated with the TLR4 agonist lipopolysaccharide (LPS). To evaluate the effect of TLR4 activation, NF-κB activation, IL8 secretion and expression and COX-2 expression were determined. RESULTS:TLR4 expression was significantly increased in esophageal adenocarcinoma, BE, duodenum and reflux esophagitis compared to normal squamous esophagus. LPS stimulation resulted in NF-κB activation and a dose-dependent increase of IL8 secretion and mRNA expression. The induction of IL8 was more evident in BE compared to normal squamous esophagus. Upon LPS stimulation, COX-2 expression increased significantly in ex vivo cultured BE biopsies, which was observed in both epithelium and lamina propria cells. However, no effect was found in duodenum and normal squamous esophagus biopsies. CONCLUSION:TLR4 activation in BE results in a strong increase in COX-2 and may contribute to malignant transformation.
Authors: K Burns; J Clatworthy; L Martin; F Martinon; C Plumpton; B Maschera; A Lewis; K Ray; J Tschopp; F Volpe Journal: Nat Cell Biol Date: 2000-06 Impact factor: 28.824
Authors: Masayuki Fukata; Limin Shang; Rebeca Santaolalla; John Sotolongo; Cristhine Pastorini; Cecilia España; Ryan Ungaro; Noam Harpaz; Harry S Cooper; Greg Elson; Marie Kosco-Vilbois; Julia Zaias; Maria T Perez; Lloyd Mayer; Arunan S Vamadevan; Sergio A Lira; Maria T Abreu Journal: Inflamm Bowel Dis Date: 2010-11-15 Impact factor: 5.325
Authors: Frederik Hvid-Jensen; Lars Pedersen; Asbjørn Mohr Drewes; Henrik Toft Sørensen; Peter Funch-Jensen Journal: N Engl J Med Date: 2011-10-13 Impact factor: 91.245
Authors: Kirsty F MacKenzie; Mirjam W M Van Den Bosch; Shaista Naqvi; Suzanne E Elcombe; Victoria A McGuire; Alastair D Reith; Perry J Blackshear; Jonathan L E Dean; J Simon C Arthur Journal: Mol Cell Biol Date: 2013-02-04 Impact factor: 4.272
Authors: Kathy Hormi-Carver; Xi Zhang; Hui Ying Zhang; Robert H Whitehead; Lance S Terada; Stuart J Spechler; Rhonda F Souza Journal: Cancer Res Date: 2009-01-15 Impact factor: 12.701
Authors: R Sitarz; R J Leguit; W W J de Leng; F H M Morsink; W P Polkowski; R Maciejewski; G J A Offerhaus; A N Milne Journal: Cell Oncol Date: 2009 Impact factor: 6.730
Authors: Olli Helminen; Heikki Huhta; Petri P Lehenkari; Juha Saarnio; Tuomo J Karttunen; Joonas H Kauppila Journal: Oncoimmunology Date: 2016-01-25 Impact factor: 8.110
Authors: Uma M Sachdeva; Masataka Shimonosono; Samuel Flashner; Ricardo Cruz-Acuña; Joel T Gabre; Hiroshi Nakagawa Journal: Cancer Lett Date: 2021-04-07 Impact factor: 9.756